Protein Inhibitor Clears Human Lymphoma From Mice in Just Five Days

Hopeful news came out of Weill Cornell Medical College about a drug that cleared human lymphoma from mice after just five days.

Researchers at Weill Cornell Medical College are reporting on an experimental drug that completely eradicated human lymphoma from mice in less than one week. The next step is moving from preclinical trials to clinical trials – in this case against diffuse large B-cell lymphoma (DLBCL) – the most common subtype of non-Hodgkin's lymphoma.

Their findings have been published online in the journal Cell Reports .

Examining the research

Researchers first described a powerful master regulatory transcription factor, known as Bcl6, and how it regulates the genome and makes it possible for aggressive lymphomas to survive. They then demonstrated the Bcl6 inhibitor, which is the experimental drug developed at Weill Cornell, and how it prevents the protein from having its effect.

The transcription factor Bcl6 is active in several cancers, but researchers have focused the inhibitor work on DLBCL. Senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology/Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell, explains why:

That's because we desperately need a new strategy to treat this lymphoma – many patients are resistant to currently available treatments.

Melnick's research

Melnick is the chief developer of the Bcl6 inhibitors, which he developed almost a decade ago. His work has also shown researchers can stump Bcl6 in DLBCL without causing severe side effects, in part by preserving T-cell function.

Melnick adds:

We now know the genes that Bcl6 is repressing and how that helps lymphoma develop and survive … This is wonderfully serendipitous – our drug just happens to be able to overcome both of the biological mechanisms that are key to survival of aggressive lymphoma.

No word yet on when recruiting might begin for a clinical trial.

Source: Science Codex

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...